
Katharine L Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7443873/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 2022, 139, 2499-2511.	1.4	42
2	New Directions for Mantle Cell Lymphoma in 2022. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 614-628.	3.8	14
3	Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study. Cancer Research, 2022, 82, CT138-CT138.	0.9	1
4	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 2021, 192, 1049-1053.	2.5	31
5	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet, The, 2021, 397, 892-901.	13.7	260
6	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 2021, 38, 3789-3802.	2.9	3
7	Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies Journal of Clinical Oncology, 2021, 39, 7525-7525.	1.6	1
8	Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies. Journal of Personalized Medicine, 2021, 11, 764.	2.5	30
9	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Blood, 2021, 138, 381-381.	1.4	8
10	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. Blood, 2021, 138, 1549-1549.	1.4	4
11	Autologous stem cell transplantation for untreated transformed indolent Bâ€cell lymphoma in first remission: an international, multiâ€centre propensityâ€scoreâ€matched study. British Journal of Haematology, 2020, 191, 806-815.	2.5	7
12	Event free survival at 12 months (EFS12) in stage 1 DLBCL – a reassuring milestone?. Leukemia and Lymphoma, 2020, 61, 2542-2543.	1.3	0
13	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, WaldenstrA¶m's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. Blood, 2020, 136, 8-10.	1.4	5
14	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study Journal of Clinical Oncology, 2020, 38, 8021-8021.	1.6	0
15	Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e564-e567.	0.4	4